Imbria Pharmaceuticals
Boston, US · Founded 2018 · Delaware corporation · 7 known investors
Find your way into Imbria Pharmaceuticals
1,596 people in our graph share verified history with the Imbria Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Stephane Kurganunlockedknows Alvin Shih · together at McKinsey & Company (overlapped)
×3knows the team · via McKinsey & Company
×3knows the team · via Northwestern University - Kellogg School of Management
×2knows the team · via Credit Suisse
knows the team · via Axcella Health
knows the team · via Deutsche Bank
Founders & leadership
PC
Pavan CheruvuExecutive
AS
Alvin ShihinExecutiveHe previously served as CEO at Disarm Therapeutics (acquired by Eli Lilly) and Enzyvant Therapeutics (acquired by Sumitomo), held a role at Catamaran Bio, and has background in medicine and management consulting.
KJ
Komal JoshiinExecutiveKomal Joshi is an Executive Officer at Imbria Pharmaceuticals with over 20 years of experience in life sciences, investment banking, and institutional equity research, including roles that involved raising capital and leading IPO transactions. He holds an MBA from Columbia Business School.
PB
Pieter BoelhouwerNamed on SEC filing
DC
David-Alexandre C. GrosNamed on SEC filing
Board
CD
LR
Luse RebeccaBoard director
AL
ZA
Zina Affas BesseBoard director
KH
Ken HorneBoard director
Investors · 7
Catalio Capital ManagementreportedNew York
RA CapitalreportedBoston
SV Health InvestorsreportedBoston · $1M – $20M
Also in the syndicate · 4
AN VenturesAXA IM AltsCytokinetics, Inc.Deep Track Capitallead
Reported raises · per SEC filings
Form D private placements$147.7M disclosed across 3 rounds · 2018–2025
▶$66.7MraisedDec 2025 · 10 investors · BiotechnologyRule 506(b)
▶$66.7MraisedDec 2025 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pavan CheruvuDirector
- Charles DunnDirector
- Alvin ShihExecutive Officer, Director
- Luse RebeccaDirector
- Ken HorneDirector
- Komal JoshiExecutive Officer
- Andrew LevinDirector
- Zina Affas BesseDirector
- Offering amount
- $144.2M
- Amount sold
- $66.7M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.7MraisedJul 2020 · 4 investors · PharmaceuticalsRule 506(b)
▶$40.7MraisedJul 2020 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LevinDirector
- David-Alexandre C. GrosExecutive Officer
- James JanuzziDirector
- Offering amount
- $80.7M
- Amount sold
- $40.7M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$40.2MraisedJul 2018 · 3 investors · PharmaceuticalsRule 506(b)
▶$40.2MraisedJul 2018 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LevinDirector
- Pieter BoelhouwerDirector
- David-Alexandre C. GrosExecutive Officer, Director
- Offering amount
- $40.2M
- Amount sold
- $40.2M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Imbria Pharmaceuticals's investors?
- Imbria Pharmaceuticals's investors include Catalio Capital Management, RA Capital, SV Health Investors.
- How much funding has Imbria Pharmaceuticals raised?
- Imbria Pharmaceuticals has disclosed $147.7M raised across 3 rounds.
- Where is Imbria Pharmaceuticals headquartered?
- Imbria Pharmaceuticals is headquartered in Boston, US.